Effect of the Timing of Amubarvimab/Romlusevimab (BRII-196/198) Administration on Progression to Severe Disease in Elderly Patients with COVID-19 Infection: A Retrospective Cohort Study.

Yonghao XuYing LiuRuiqiang ZhengShujie SiYin XiXilong DengGang WangLiang ZhouManshu LiYa WangShuo ZhangJianfeng XieXiaoqing LiuYi YangXiaoping Tang

Published in: Intensive care research (2023)

In elderly patients with mild or moderate COVID-19 disease, who do not require oxygen support and had the risk factors for disease progression to severe COVID-19 disease, the administration of BRII-196/198 within 3 days resulted in a beneficial trend in terms of preventing disease progression.

Keyphrases

coronavirus disease
sars cov
early onset
drug induced
respiratory syndrome coronavirus